Martin Madaus Elected to Haemonetics Board of Directors
Rhea-AI Summary
Haemonetics (NYSE: HAE) announced that Dr. Martin Madaus has been elected to its Board of Directors, effective July 24, 2026. He brings over 30 years of leadership in diagnostics and life sciences, including CEO roles at Ortho Clinical Diagnostics, Millipore and Roche Diagnostics North America.
Dr. Madaus is currently Senior Operating Executive at The Carlyle Group and serves as Chair of Repligen and a board member of Azenta. He holds a Doctor of Veterinary Medicine from the University of Munich and a Ph.D. in Veterinary Medicine from the Veterinary School of Hanover.
Positive
- None.
Negative
- None.
AI-generated analysis. How Rhea-AI works. Not financial advice.
Dr. Madaus brings more than 30 years of leadership experience in the diagnostics and life sciences tools industries, having helped drive corporate strategy, commercial growth and operational transformation as both a chief executive officer and a board member. He currently serves as Senior Operating Executive at The Carlyle Group, where since 2019 he has advised on healthcare investments and portfolio company performance. Previously, Dr. Madaus served as Chairman and Chief Executive Officer of Ortho Clinical Diagnostics, Inc. (now QuidelOrtho Corporation), a global provider of in vitro diagnostics, where he led the company's business turnaround following its carve-out from Johnson & Johnson. Earlier, as Chairman, President and Chief Executive Officer of Millipore Corporation, he led the company's transformation into a leading life sciences company, culminating in its acquisition by Merck KGaA in 2010. Before Millipore, Dr. Madaus served as President and Chief Executive Officer of Roche Diagnostics North America.
In addition to his executive leadership experience, Dr. Madaus is an active board leader and currently serves as Chair of the Board of Repligen Corporation and as a member of the board of directors of Azenta, Inc. He holds a Doctor of Veterinary Medicine from the University of
"Martin has built and transformed some of the world's leading healthcare companies and brings deep operational, commercial and strategic leadership experience to our Board," said Ellen Zane, Chair of Haemonetics' Board of Directors. "His track record of leading complex global organizations, driving operational excellence and creating shareholder value will be invaluable as Haemonetics continues to execute its strategy, expand its leadership across attractive end markets and deliver long-term value for patients, customers and shareholders."
ABOUT HAEMONETICS
Haemonetics is a global medical technology company dedicated to improving the quality, effectiveness and efficiency of health care. Our Apheresis business features proprietary technologies designed to enhance safety, yield, donor satisfaction and operational efficiency for plasma and blood collectors around the world. Our MedSurg business offers Blood Management Technologies to help inform treatment decisions and optimize the management of blood products, and Interventional Technologies, including advanced vascular closure systems and sensor-guided technologies, designed to drive procedural effectiveness and elevate the patient experience. To learn more about Haemonetics, visit www.haemonetics.com.
Investor Contacts: | |
Olga Guyette, Vice President-Investor Relations & Treasury (781) 356-9763 | David Trenk, Sr. Manager-Investor Relations (203) 733-4987 |
Media Contact: Josh Gitelson, Sr. Director-Global Communications (781) 356-9776 |
View original content to download multimedia:https://www.prnewswire.com/news-releases/martin-madaus-elected-to-haemonetics-board-of-directors-302836656.html
SOURCE Haemonetics Corporation